Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients.
Eline L GiraudNaomi T JessurunFlorence P A M van HunselEugene P van PuijenbroekAstrid van TubergenPeter M Ten KloosterHarald E VonkemanPublished in: Expert opinion on drug safety (2020)
Although ADR data in the DREAM-RA registry were partly comparable with data in the SmPCs, RWD from this patient registry provided an added value to the currently available information on the incidences of ADRs associated with DMARDs in RA patients as described in SmPCs.
Keyphrases
- adverse drug
- rheumatoid arthritis patients
- disease activity
- electronic health record
- rheumatoid arthritis
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- systemic lupus erythematosus
- big data
- emergency department
- ankylosing spondylitis
- peritoneal dialysis
- prognostic factors
- healthcare
- machine learning
- data analysis
- interstitial lung disease